Race Oncology (ASX:RAC) - Managing Director and CEO, Phillip Lynch
Managing Director and CEO, Phillip Lynch
Source: Race Oncology
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Race Oncology (RAC) is granted its sixth US patent for its cancer drug, Zantrene, valid until July 2034
  • The company says the new patent provides Race with further protection around uses of Zantrene, allowing it to further expand its therapeutic utility
  • Race intends to continue exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, along with the use of the treatment as a chemotherapeutic agent
  • Race Oncology is trading down 1.58 per cent at $3.11 at 10:55 am AEDT

Race Oncology (RAC) has locked in its sixth US patent for its cancer drug, Zantrene.

Zantrene is a phase 2/3 cancer drug that is an inhibitor of the fat mass and obesity associated (FTO) protein, which has been shown to be the genetic driver of a diverse range of cancers when overexpressed.

The new US patent, entitled “Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof”, expires on July 25, 2034.

The company said the new patent further expanded the therapeutic utility of Zantrene, focusing on methods that improve the therapeutic efficacy of Zantrene and reducing side effects.

“The new US patent provides Race with further protection around uses of Zantrene (and related chemical structures) that improve the efficacy of Zantrene treatments,” Race’s CEO Phillip Lynch said.

The new work builds on Race’s existing Zantrene patents, the first of which was granted in 2018.

Race said it would continue to explore the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers, along with the use of the treatment as a chemotherapeutic agent.

Race Oncology was trading down 1.58 per cent at $3.11 at 10:55 am AEDT.

RAC by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…